Drugs.com - Clinical Trials

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Feb. 5, 2025-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today...

Feb 9, 2025 - 21:44
 0
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Feb. 5, 2025-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today...
Read More

Tags:

Previous Article

EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Tr...

Next Article

Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrat...

Related Posts

U.S. FDA Grants Orphan Drug Designation to Ariceum Therapeutics’ Proprietary Radiopharmaceutical Cancer Therapy

U.S. FDA Grants Orphan Drug Designation to Ariceum Ther...

Feb 10, 2025  0

Amgen and Kyowa Kirin Provide Top-Line Results from Rocatinlimab Phase 3 Ignite Study in Adults with Moderate to Severe Atopic Dermatitis

Amgen and Kyowa Kirin Provide Top-Line Results from Roc...

Mar 9, 2025  0

Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program

Omeros Corporation Provides Update of Ongoing Zalteniba...

Mar 26, 2025  0